138 related articles for article (PubMed ID: 9023649)
21. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers.
Nakashima M; Uematsu T; Kosuge K; Okuyama Y; Morino A; Ozaki M; Takebe Y
J Clin Pharmacol; 1994 Sep; 34(9):930-7. PubMed ID: 7983237
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
Teng R; Harris SC; Nix DE; Schentag JJ; Foulds G; Liston TE
J Antimicrob Chemother; 1995 Aug; 36(2):385-94. PubMed ID: 8522468
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin.
Child J; Andrews JM; Wise R
Antimicrob Agents Chemother; 1995 Feb; 39(2):513-5. PubMed ID: 7726523
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of temafloxacin in humans after single oral doses.
Granneman GR; Carpentier P; Morrison PJ; Pernet AG
Antimicrob Agents Chemother; 1991 Mar; 35(3):436-41. PubMed ID: 2039194
[TBL] [Abstract][Full Text] [Related]
25. Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization.
Kamberi M; Kotegawa T; Tsutsumi K; Nakamura K; Nakano S
Eur J Clin Pharmacol; 1998 Oct; 54(8):633-7. PubMed ID: 9860151
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and tolerability of prulifloxacin after single oral administration.
Picollo R; Brion N; Gualano V; Millérioux L; Marchetti M; Rosignoli MT; Dionisio P
Arzneimittelforschung; 2003; 53(3):201-5. PubMed ID: 12705176
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.
Kozawa O; Uematsu T; Matsuno H; Niwa M; Nagashima S; Kanamaru M
Antimicrob Agents Chemother; 1996 Dec; 40(12):2824-8. PubMed ID: 9124849
[TBL] [Abstract][Full Text] [Related]
28. Clinafloxacin-theophylline drug interaction.
Matuschka PR; Vissing RS
Ann Pharmacother; 1995 Apr; 29(4):378-80. PubMed ID: 7633015
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg.
Montay G; Bruno R; Vergniol JC; Ebmeier M; Le Roux Y; Guimart C; Frydman A; Chassard D; Thebault JJ
J Clin Pharmacol; 1994 Nov; 34(11):1071-6. PubMed ID: 7876398
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects.
O'Grady J; Briggs A; Atarashi S; Kobayashi H; Smith RL; Ward J; Ward C; Milatovic D
Xenobiotica; 2001 Nov; 31(11):811-22. PubMed ID: 11765143
[TBL] [Abstract][Full Text] [Related]
31. Effect of age and gender on the pharmacokinetics of grepafloxacin.
Efthymiopoulos C; Bramer SL; Maroli A
Clin Pharmacokinet; 1997; 33 Suppl 1():9-17. PubMed ID: 9433651
[TBL] [Abstract][Full Text] [Related]
32. The influence of age and gender on the pharmacokinetics of moxifloxacin.
Sullivan JT; Lettieri JT; Liu P; Heller AH
Clin Pharmacokinet; 2001; 40 Suppl 1():11-8. PubMed ID: 11352437
[TBL] [Abstract][Full Text] [Related]
33. Effect of antacid medication on the pharmacokinetics of temafloxacin.
Granneman GR; Stephan U; Birner B; Sörgel F; Mukherjee D
Clin Pharmacokinet; 1992; 22 Suppl 1():83-9. PubMed ID: 1319875
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of temafloxacin in patients with liver impairment.
Granneman GR; Mahr G; Locke C; Nickel P; Kirch W; Fabian W; Kinzig M; Naber KG; Sörgel F
Clin Pharmacokinet; 1992; 22 Suppl 1():24-32. PubMed ID: 1319868
[TBL] [Abstract][Full Text] [Related]
35. Drug interactions with clinafloxacin.
Randinitis EJ; Alvey CW; Koup JR; Rausch G; Abel R; Bron NJ; Hounslow NJ; Vassos AB; Sedman AJ
Antimicrob Agents Chemother; 2001 Sep; 45(9):2543-52. PubMed ID: 11502527
[TBL] [Abstract][Full Text] [Related]
36. Fluoroquinolone-induced retinal degeneration in cats.
Wiebe V; Hamilton P
J Am Vet Med Assoc; 2002 Dec; 221(11):1568-71. PubMed ID: 12479325
[TBL] [Abstract][Full Text] [Related]
37. A review of the pharmacokinetic profile of temafloxacin.
Dudley MN
J Antimicrob Chemother; 1991 Dec; 28 Suppl C():55-64. PubMed ID: 1664830
[TBL] [Abstract][Full Text] [Related]
38. High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans.
Vree TB; van den Biggelaar-Martea M; Imbimbo BP
Eur J Drug Metab Pharmacokinet; 1992; 17(1):45-9. PubMed ID: 1323466
[TBL] [Abstract][Full Text] [Related]
39. Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.
Granneman GR; Braeckman R; Kraut J; Shupien S; Craft JC
Antimicrob Agents Chemother; 1991 Nov; 35(11):2345-51. PubMed ID: 1666497
[TBL] [Abstract][Full Text] [Related]
40. Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis.
Triger DR; Granai F; Woodcock J; Wise R; Imbimbo BP
Hepatology; 1993 Oct; 18(4):847-52. PubMed ID: 8406358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
